Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: A systematic literature review (SLR)
Fig 5
Median OS (months) at third line[15, 49, 52, 60, 63].
2L = second line; CAV = cyclophosphamide, doxorubicin and vincristine; CR = complete response; CT = chemotherapy; n = number of patients; OS = overall survival; PD = progressive disease; PR = partial response; pts = patients; SD = stable disease.